Irish drugmaker Shire is considering a fifth offer from Takeda, after its Japanese rival once again sweetened its bid for the firm.
I rish drugmaker Shire is considering a fifth offer from Takeda, after its Japanese rival once again sweetened its bid for the firm.
Shire confirmed it had received a better offer but did not disclose the details. The previous offer on Friday from Takeda valued it at £42.8bn, which the FTSE 100 firm had said it was considering. Takeda was unavailable for comment.
Any tie-up could create a global pharmaceutical powerhouse with close to £22bn of annual sales, roughly equivalent in size to Britain’s AstraZeneca.
But Takeda’s tilt has concerned some analysts who have raised warnings about the large amount of debt the smaller Japanese company would be taking on.
